Summit Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Summit Therapeutics Inc. (NASDAQ: SMMT) is a clinical-stage biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Originally focused on anti-infectives, the company executed a decisive strategic pivot in late 2022 when it licensed ivonescimab (SMT112) from Akeso Inc. for development and commercialization in North America, South America, Europe, the Middle East, Africa, and Japan. Ivonescimab is a novel, investigational bispecific antibody designed to target both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Summit is headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Summit has strategically shifted its core focus from anti-infectives to oncology, centering its business model on the clinical development and potential commercialization of ivonescimab (SMT112), a novel bispecific antibody targeting PD-1 and VEGF-A.
Expected impact: Establish ivonescimab as a cornerstone oncology treatment, initially targeting non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) in licensed territories.
Preparing the operational infrastructure for the potential commercial launch of ivonescimab in the United States, including validating manufacturing and drug supply processes with a U.S.-based manufacturer.
Expected impact: Ensure reliable, high-quality drug supply and commercial distribution capabilities to support rapid market uptake upon regulatory approval.
Commenced an underwritten public offering of $500.0 million of common stock (with an underwriters' option for an additional $75.0 million) to fund the clinical development of ivonescimab, working capital, and general corporate purposes.
Expected impact: Address the substantial doubt regarding the company's ability to continue as a going concern by significantly extending its cash runway to support ongoing Phase III trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. This collaboration evaluates ivonescimab in combination with GSK's novel B7-H3-targeted antibody-drug conjugate (ADC), risvutatug rezetecan (GSK'227), across multiple solid tumor settings, including small cell lung cancer (SCLC). It expands ivonescimab's therapeutic reach into combination regimens with ADCs.
Terms: Mutually non-exclusive agreement. Summit will supply ivonescimab for the study, while GSK will manage and fund the day-to-day clinical operations. Each party maintains rights to their respective products.
Medium. Evaluates ivonescimab in combination with Revolution Medicines' clinical-stage RAS(ON) inhibitors (daraxonrasib, zoldonrasib, and elironrasib) in solid tumors with RAS mutations, including NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer.
Terms: Summit supplies ivonescimab for clinical research, and Revolution Medicines acts as the study sponsor. Patient enrollment commenced in Q1 2026.
Medium. A collaboration with the European Head and Neck Oncology and Radiotherapy Group to evaluate ivonescimab monotherapy and in combination with ligufalimab (Akeso's anti-CD47 antibody) against pembrolizumab in head and neck cancer (Phase III ILLUMINE study).
Terms: The study is sponsored by GORTEC and conducted in Europe and China, with potential expansion into the United States by Summit.